{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:22:31Z","timestamp":1794565351563,"version":"4.9.1"},"reference-count":56,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"9","license":[{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>The BCR::ABL1 gene fusion initiates chronic myeloid leukemia (CML); however, evidence has accumulated from studies of highly selected cohorts that variants in other cancer-related genes are associated with treatment failure. Nevertheless, the true incidence and impact of additional genetic abnormalities (AGA) at diagnosis of chronic phase (CP)-CML is unknown. We sought to determine whether AGA at diagnosis in a consecutive imatinib-treated cohort of 210 patients enrolled in the TIDEL-II trial influenced outcome despite a highly proactive treatment intervention strategy. Survival outcomes including overall survival, progression-free survival, failure-free survival, and BCR::ABL1 kinase domain mutation acquisition were evaluated. Molecular outcomes were measured at a central laboratory and included major molecular response (MMR, BCR::ABL1 \u22640.1%IS), MR4 (BCR::ABL1 \u22640.01%IS), and MR4.5 (BCR::ABL1 \u22640.0032%IS). AGA included variants in known cancer genes and novel rearrangements involving the formation of the Philadelphia chromosome. Clinical outcomes and molecular response were assessed based on the patient's genetic profile and other baseline factors. AGA were identified in 31% of patients. Potentially pathogenic variants in cancer-related genes were detected in 16% of patients at diagnosis (including gene fusions and deletions) and structural rearrangements involving the Philadelphia chromosome (Ph-associated rearrangements) were detected in 18%. Multivariable analysis demonstrated that the combined genetic abnormalities plus the EUTOS long-term survival clinical risk score were independent predictors of lower molecular response rates and higher treatment failure. Despite a highly proactive treatment intervention strategy, first-line imatinib-treated patients with AGA had poorer response rates. These data provide evidence for the incorporation of genomically-based risk assessment for CML.<\/jats:p>","DOI":"10.3324\/haematol.2022.282184","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T04:25:50Z","timestamp":1679545550000},"page":"2380-2395","source":"Crossref","is-referenced-by-count":18,"title":["Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention"],"prefix":"10.3324","volume":"108","author":[{"given":"Naranie","family":"Shanmuganathan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Wadham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NurHezrin","family":"Shahrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghua","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verity","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung Hoow","family":"Kok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob M.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalie R.","family":"Kenyon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria S.","family":"Pagani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes S.M.","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Grigg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony K.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony P.","family":"Schwarer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi","family":"Braley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley","family":"Altamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamish S.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas W.","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Branford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,3,23]]},"reference":[{"key":"51370","doi-asserted-by":"crossref","unstructured":"Hochhaus A, Larson RA, Guilhot F. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017; 376(10):917-927.","DOI":"10.1056\/NEJMoa1609324"},{"key":"51371","doi-asserted-by":"crossref","unstructured":"Hehlmann R, Lauseker M, Sau\u00dfele S. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017; 31(11):2398-2406.","DOI":"10.1038\/leu.2017.253"},{"key":"51372","doi-asserted-by":"crossref","unstructured":"Hochhaus A, Saglio G, Hughes TP. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016; 30(5):1044-1054.","DOI":"10.1038\/leu.2016.5"},{"key":"51373","doi-asserted-by":"crossref","unstructured":"Cortes JE, Saglio G, Kantarjian HM. Final 5-year study results of DASISION: the Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial. J Clin Oncol. 2016; 34(20):2333-2340.","DOI":"10.1200\/JCO.2015.64.8899"},{"key":"51374","doi-asserted-by":"crossref","unstructured":"Cortes JE, Gambacorti-Passerini C, Deininger MW. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018; 36(3):231-237.","DOI":"10.1200\/JCO.2017.74.7162"},{"key":"51375","doi-asserted-by":"crossref","unstructured":"Bower H, Bj\u00f6rkholm M, Dickman PW, H\u00f6glund M, Lambert PC, Andersson TML. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016; 34(24):2851-2857.","DOI":"10.1200\/JCO.2015.66.2866"},{"key":"51376","doi-asserted-by":"crossref","unstructured":"Hochhaus A, Baccarani M, Silver RT. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020; 34(4):966-984.","DOI":"10.1038\/s41375-020-0776-2"},{"key":"51377","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia (version 3.2022). 2023."},{"key":"51378","doi-asserted-by":"crossref","unstructured":"O'Hare T, Eide CA, Deininger MWN. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood. 2007; 110(7):2242-2249.","DOI":"10.1182\/blood-2007-03-066936"},{"key":"51379","doi-asserted-by":"crossref","unstructured":"Soverini S, Colarossi S, Gnani A. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res. 2006; 12(24):7374-7379.","DOI":"10.1158\/1078-0432.CCR-06-1516"},{"key":"51380","doi-asserted-by":"crossref","unstructured":"Jabbour E, Kantarjian H, Jones D. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia. 2006; 20(10):1767-1773.","DOI":"10.1038\/sj.leu.2404318"},{"key":"51381","doi-asserted-by":"crossref","unstructured":"Calabretta B, Perrotti D. The biology of CML blast crisis. Blood. 2004; 103(11):4010-4022.","DOI":"10.1182\/blood-2003-12-4111"},{"key":"51382","doi-asserted-by":"crossref","unstructured":"Radich JP. The biology of CML blast crisis. Hematology Am Soc Hematol Educ Program. 2007;384-391.","DOI":"10.1182\/asheducation-2007.1.384"},{"key":"51383","doi-asserted-by":"crossref","unstructured":"Koptyra M, Cramer K, Slupianek A, Richardson C, Skorski T. BCR\/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress. Leukemia. 2008; 22(10):1969-1972.","DOI":"10.1038\/leu.2008.78"},{"key":"51384","doi-asserted-by":"crossref","unstructured":"Bolton-Gillespie E, Schemionek M, Klein HU. Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. Blood. 2013; 121(20):4175-4183.","DOI":"10.1182\/blood-2012-11-466938"},{"key":"51385","doi-asserted-by":"crossref","unstructured":"Kim T, Tyndel MS, Kim HJ. Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy. Blood. 2017; 129(1):38-47.","DOI":"10.1182\/blood-2016-04-708560"},{"key":"51386","doi-asserted-by":"crossref","unstructured":"Branford S, Wang P, Yeung DT. Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. Blood. 2018; 132(9):948-961.","DOI":"10.1182\/blood-2018-02-832253"},{"key":"51387","doi-asserted-by":"crossref","unstructured":"Thomson DW, Shahrin NH, Wang PPS. Aberrant RAG-mediated recombination contributes to multiple structural rearrangements in lymphoid blast crisis of chronic myeloid leukemia. Leukemia. 2020; 34(8):2051-2063.","DOI":"10.1038\/s41375-020-0751-y"},{"key":"51388","doi-asserted-by":"crossref","unstructured":"Fernandes A, Shanmuganathan N, Branford S. Genomic mechanisms influencing outcome in chronic myeloid leukemia. Cancers. 2022; 14(3):620.","DOI":"10.3390\/cancers14030620"},{"key":"51389","doi-asserted-by":"crossref","unstructured":"Shen MM. Chromoplexy: a new category of complex rearrangements in the cancer genome. Cancer Cell. 2013; 23(5):567-569.","DOI":"10.1016\/j.ccr.2013.04.025"},{"key":"51390","doi-asserted-by":"crossref","unstructured":"Baca SC, Prandi D, Lawrence MS. Punctuated evolution of prostate cancer genomes. Cell. 2013; 153(3):666-677.","DOI":"10.1016\/j.cell.2013.03.021"},{"key":"51391","doi-asserted-by":"crossref","unstructured":"Nteliopoulos G, Bazeos A, Claudiani S. Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors. Haematologica. 2019; 104(12):2400-2409.","DOI":"10.3324\/haematol.2018.200220"},{"key":"51392","doi-asserted-by":"crossref","unstructured":"Adnan Awad S, Kankainen M, Ojala T. Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia. Blood Adv. 2020; 4(3):546-559.","DOI":"10.1182\/bloodadvances.2019000943"},{"key":"51393","doi-asserted-by":"crossref","unstructured":"Pfirrmann M, Clark RE, Prejzner W. The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. Leukemia. 2020; 34(8):2138-2149.","DOI":"10.1038\/s41375-020-0931-9"},{"key":"51394","doi-asserted-by":"crossref","unstructured":"Yeung DT, Osborn MP, White DL. TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Blood. 2015; 125(6):915-923.","DOI":"10.1182\/blood-2014-07-590315"},{"key":"51395","doi-asserted-by":"crossref","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013; 122(6):872-884.","DOI":"10.1182\/blood-2013-05-501569"},{"key":"51396","doi-asserted-by":"crossref","unstructured":"Shanmuganathan N, Wadham C, Thomson D. RNA-based targeted gene sequencing improves the diagnostic yield of mutant detection in chronic myeloid leukemia. J Mol Diagn. 2022; 24(7):802-822.","DOI":"10.1016\/j.jmoldx.2022.04.004"},{"key":"51397","doi-asserted-by":"crossref","unstructured":"Li MM, Datto M, Duncavage EJ. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017; 19(1):4-23.","DOI":"10.1016\/j.jmoldx.2016.10.002"},{"key":"51398","doi-asserted-by":"crossref","unstructured":"Horak P, Griffith M, Danos AM. Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Genet Med. 2022; 24(5):986-998.","DOI":"10.1016\/j.gim.2022.05.017"},{"key":"51399","doi-asserted-by":"crossref","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc B (Methodological). 1995; 57(1):289-300.","DOI":"10.1111\/j.2517-6161.1995.tb02031.x"},{"key":"51400","doi-asserted-by":"crossref","unstructured":"Zhang X, Li Z, Qin Y, Gale RP, Huang X, Jiang Q. Correlations between mutations in cancer-related genes, therapy responses and outcomes of the 3rd generation tyrosine kinase-inhibitor (TKI) in persons with chronic myeloid leukemia failing prior TKI-therapy. Blood. 2021; 138(Suppl 1)","DOI":"10.1182\/blood-2021-150020"},{"key":"51401","doi-asserted-by":"crossref","unstructured":"Ochi Y, Yoshida K, Huang Y-J. Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia. Nat Commun. 2021; 12(1):2833.","DOI":"10.1038\/s41467-021-23097-w"},{"key":"51402","doi-asserted-by":"crossref","unstructured":"Branford S, Kim DDH, Apperley JF. Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia. 2019; 33(8):1835-1850.","DOI":"10.1038\/s41375-019-0512-y"},{"key":"51403","doi-asserted-by":"crossref","unstructured":"Johnson SM, Ramkissoon L, Haberberger J. Comprehensive genomic characterization of ASXL1 C.1934dupG (p.G646fs*12) versus other ASXL1 mutations in myeloid neoplasia. Blood. 2021; 138(Suppl 1):3466-3466.","DOI":"10.1182\/blood-2021-151796"},{"key":"51404","doi-asserted-by":"crossref","unstructured":"Alberti MO, Srivatsan SN, Shao J. Discriminating a common somatic ASXL1 mutation (c.1934dup; p.G646Wfs*12) from artifact in myeloid malignancies using NGS. Leukemia. 2018; 32(8):1874-1878.","DOI":"10.1038\/s41375-018-0193-y"},{"key":"51405","doi-asserted-by":"crossref","unstructured":"Rahmani NE, Ramachandra N, Sahu S. ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine. Blood Cancer J. 2021; 11(9):157.","DOI":"10.1038\/s41408-021-00541-0"},{"key":"51406","doi-asserted-by":"crossref","unstructured":"Wang L, Birch NW, Zhao Z. Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated leukemia. Nat Cancer. 2021; 2(5):515-526.","DOI":"10.1038\/s43018-021-00199-4"},{"key":"51407","doi-asserted-by":"crossref","unstructured":"Li X, Heyer W-D. Homologous recombination in DNA repair and DNA damage tolerance. Cell Res. 2008; 18(1):99-113.","DOI":"10.1038\/cr.2008.1"},{"key":"51408","doi-asserted-by":"crossref","unstructured":"Toh M, Ngeow J. Homologous recombination deficiency: cancer predispositions and treatment implications. Oncologist. 2021; 26(9):e1526-e1537.","DOI":"10.1002\/onco.13829"},{"key":"51409","doi-asserted-by":"crossref","unstructured":"Chakraborty A, Tapryal N, Venkova T. Classical non-homologous end-joining pathway utilizes nascent RNA for error-free double-strand break repair of transcribed genes. Nat Commun. 2016; 7(1):13049.","DOI":"10.1038\/ncomms13049"},{"key":"51410","doi-asserted-by":"crossref","unstructured":"Chang HHY, Pannunzio NR, Adachi N, Lieber MR. Non-homologous DNA end joining and alternative pathways to double-strand break repair. Nat Rev Mol Cell Biol. 2017; 18(8):495-506.","DOI":"10.1038\/nrm.2017.48"},{"key":"51411","doi-asserted-by":"crossref","unstructured":"Huntly BJ, Bench A, Green AR. Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood. 2003; 102(4):1160-1168.","DOI":"10.1182\/blood-2003-01-0123"},{"key":"51412","doi-asserted-by":"crossref","unstructured":"Sinclair PB, Nacheva EP, Leversha M. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood. 2000; 95(3):738-744.","DOI":"10.1182\/blood.V95.3.738.003k21_738_743"},{"key":"51413","doi-asserted-by":"crossref","unstructured":"Graux C, Cools J, Melotte C. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet. 2004; 36(10):1084-1089.","DOI":"10.1038\/ng1425"},{"key":"51414","doi-asserted-by":"crossref","unstructured":"Naumann S, Decker HJ. Genesis of variant Philadelphia chromosome translocations in chronic myelocytic leukemia. Cancer Genet Cytogenet. 2003; 147(1):18-22.","DOI":"10.1016\/S0165-4608(03)00128-6"},{"key":"51415","doi-asserted-by":"crossref","unstructured":"Fitzgerald PH, Morris CM. Complex chromosomal translocations in the Philadelphia chromosome leukemias: serial translocations or a concerted genomic rearrangement?. Cancer Genet Cytogenet. 1991; 57(2):143-151.","DOI":"10.1016\/0165-4608(91)90145-K"},{"key":"51416","doi-asserted-by":"crossref","unstructured":"Licht JD, Chomienne C, Goy A. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood. 1995; 85(4):1083-1094.","DOI":"10.1182\/blood.V85.4.1083.bloodjournal8541083"},{"key":"51417","doi-asserted-by":"crossref","unstructured":"Amare PK, Baisane C, Nair R. Characterization of cryptic rearrangements, deletion, complex variants of PML, RARA in acute promyelocytic leukemia. Indian J Hum Genet. 2011; 17(2):54-58.","DOI":"10.4103\/0971-6866.86174"},{"key":"51418","doi-asserted-by":"crossref","unstructured":"Wilde L, Cooper J, Wang Z-X, Liu J. Clinical, cytogenetic, and molecular findings in two cases of variant t(8;21) acute myeloid leukemia (AML). Front Oncol. 2019; 9:1016.","DOI":"10.3389\/fonc.2019.01016"},{"key":"51419","doi-asserted-by":"crossref","unstructured":"Ishii Y, Sashida G, Takaku TI, Sumi M, Nakajima A, Ohyashiki K. Cryptic chromosomal anomaly in a patient with acute myeloid leukemia leading to AML1\/ETO fusion with unfavorable prognostic factors. Cancer Genet Cytogenet. 2005; 160(1):94-95.","DOI":"10.1016\/j.cancergencyto.2004.11.006"},{"key":"51420","doi-asserted-by":"crossref","unstructured":"Meyer C, Burmeister T, Gr\u00f6ger D. The MLL recombinome of acute leukemias in 2017. Leukemia. 2018; 32(2):273-284.","DOI":"10.1038\/leu.2017.213"},{"key":"51421","doi-asserted-by":"crossref","unstructured":"Andersson AK, Ma J, Wang J. The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. Nat Genet. 2015; 47(4):330-337.","DOI":"10.1038\/ng.3230"},{"key":"51422","doi-asserted-by":"crossref","unstructured":"Dohner H, Estey E, Grimwade D. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017; 129(4):424-447.","DOI":"10.1182\/blood-2016-08-733196"},{"key":"51423","doi-asserted-by":"crossref","unstructured":"Guglielmelli P, Lasho TL, Rotunno G. MIPSS70: mutation-enhanced International Prognostic Score system for transplantation-age patients with primary myelofibrosis. J Clin Oncol. 2017; 36(4):310-318.","DOI":"10.1200\/JCO.2017.76.4886"},{"key":"51424","doi-asserted-by":"crossref","unstructured":"Khoury JD, Solary E, Abla O. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022; 36(7):1703-1719.","DOI":"10.1038\/s41375-022-01613-1"},{"key":"51425","doi-asserted-by":"crossref","unstructured":"Arber DA, Orazi A, Hasserjian RP. International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: integrating morphological, clinical, and genomic data. Blood. 2022; 140(11):1200-1228.","DOI":"10.1182\/blood.2022015850"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.282184\/75451","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.282184\/75946","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11027\/75451","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:03:45Z","timestamp":1794045825000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2022.282184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,23]]},"references-count":56,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.282184","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,23]]}}}